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Abstract 
Background: Patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) report difficulty with sleep.
Methods: We examined the effect of omalizumab on sleep‑related outcomes during 3–6 months omalizumab 
or placebo treatment and a 16‑week follow‑up period within three Phase III double‑blind randomized placebo‑
controlled pivotal trials in CIU/CSU: ASTERIA I, ASTERIA II, and GLACIAL. Sleep quality was assessed in all three studies 
using sleep‑related questions included in an electronic diary, the Chronic Urticaria Quality of Life Questionnaire, and 
the Medical Outcomes Study Sleep Scale. Score changes from baseline in the treatment arms were compared with 
that in the placebo arm and adjusted for baseline score and weight. We also examined correlations of sleep scores at 
baseline, week 12, and week 24 and the slopes of change between sleep and itch and hive.
Results: Patients treated with omalizumab reported a larger reduction in sleep problems than those in the placebo 
arm; omalizumab 300 mg demonstrated the greatest improvement on all sleep components among all treatment 
arms. The largest reduction in sleep problems was reported within the first 4 weeks of therapy. After treatment discon‑
tinuation, sleep quality worsened. Sleep scores demonstrated moderate‑to‑strong correlation between them, and the 
change in sleep scores was associated with changes in itch and hives.
Conclusions: Improvement in sleep was reported after the first dose of omalizumab. Sleep continued to improve 
throughout the active treatment period. Patients receiving omalizumab 300 mg achieved greater improvement in 
sleep than those in other treatment arms.
Trial registration ClinicalTrials.gov, NCT01287117 (ASTERIA I), NCT01292473 (ASTERIA II), and NCT01264939 (GLACIAL)
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Background
The Institute of Medicine has warned that chronic 
sleep disorder and wakefulness adversely impact health 
and longevity [1]. Many chronic conditions are asso-
ciated with impairments of sleep quantity or quality 
[2–5]. Chronic idiopathic urticaria (CIU), also known as 
chronic spontaneous urticaria (CSU), is a disorder char-
acterized by chronic hives, itch, and often angioedema 
that may lead to difficulty initiating or maintaining sleep 
or poor sleep quality [6–12]. CIU/CSU patients reported 
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adequate sleep [7–11]. In these patients, poor sleep 
causes fatigue and diminishes physical and emotional 
well-being [6]. In an Internet survey of patients with 
chronic urticaria, 48  % of respondents reported that 
sleep disturbances related to chronic urticaria were not 
adequately addressed [9]. When compared with patients 
with heart disease, patients with chronic urticaria report 
more difficulty with sleep disruption [10].
Omalizumab is a humanized anti-immunoglobulin E 
antibody indicated for CIU/CSU in adults and adoles-
cents who remain symptomatic despite H1-antihistamine 
treatment [13], as reported in the pivotal clinical studies 
[14–16]. Omalizumab, 150 or 300 mg, given as an every-
4-week subcutaneous injection, significantly reduces dis-
ease activity, improves CIU/CSU symptoms, and is well 
tolerated in patients with refractory CIU/CSU symp-
toms. The 2013 international guidelines recommend the 
addition of omalizumab (150–300  mg) to current treat-
ment for CIU/CSU patients who remain symptomatic 
despite receiving high doses of H1-antihistamines [17]. 
Phase III omalizumab CIU/CSU clinical studies collected 
sleep quality data via patient-reported outcome meas-
ures. We investigated the following research question: 
to what extent do sleep outcomes improve in CIU/CSU 
patients treated with omalizumab during 3 to 6 months 
within these three pivotal studies?
Methods
Study design
The omalizumab pivotal studies included ASTERIA I, 
ASTERIA II, and GLACIAL. Full study details are sum-
marized elsewhere [14–16]. Briefly, each study included 
patients aged 12–75 years (18–75 years in Germany per 
regulatory requirements) with CIU/CSU who remained 
symptomatic despite treatment with background ther-
apy. ASTERIA I and II allowed up to approved doses of 
H1-antihistamine [14, 16], while GLACIAL included 
patients being treated with up to 4 times approved doses 
plus H2-antihistamines, leukotriene receptor antagonists, 
or both [15]. In ASTERIA I and II, patients were rand-
omized 1:1:1:1 to receive omalizumab 75, 150, 300 mg, or 
placebo subcutaneously every 4 weeks. Patients included 
in GLACIAL were randomized 3:1 to receive omali-
zumab 300 mg or placebo every 4 weeks. Dosing contin-
ued for 24  weeks in ASTERIA I and GLACIAL and for 
12 weeks in ASTERIA II. Diphenhydramine 25 mg (up to 
3 doses in 24 h) was allowed as a rescue medication for 
itch relief in all three studies.
In all three studies, patients were followed for an addi-
tional 16 weeks of observation after the end of the treat-
ment period. Studies were conducted in accordance with 
US Food and Drug Administration regulations, the Inter-
national Conference on Harmonisation E6 Good Clinical 
Practice guidelines, the principles of the Declaration of 
Helsinki, and any other applicable country laws. Study 
protocols were reviewed and approved by each institu-
tional review board and all patients provided informed 
consent before study entry. The studies were registered 
with ClinicalTrials.gov, identifiers NCT01287117 (ASTE-
RIA I), NCT01292473 (ASTERIA II), and NCT01264939 
(GLACIAL).
Patients
Patients were eligible for study inclusion if they met indi-
vidual study age and background therapy requirements. 
Patients had a diagnosis of CIU/CSU for at least 6 months 
and presence of itch and hives for at least 8 (ASTERIA 
I and II) or more than 6 (GLACIAL) consecutive weeks 
before enrollment despite concurrent CIU/CSU therapy.
Patients reported their CIU/CSU symptoms and their 
impact on daily activities and sleep via an electronic daily 
diary [18] and paper-based patient-reported outcomes 
during office visits [baseline, weeks 4, 12, and 28 (ASTE-
RIA II), and weeks 4, 12, 24, and 40 (ASTERIA II and 
GLACIAL)]. Individual study publications provide addi-
tional details on the study design [14–16].
Sleep assessment
Sleep quality was assessed in all three studies via one 
question in the electronic diary [18], several questions 
in the Medical Outcomes Study Sleep Scale (MOS-Sleep 
Scale) [19], and the Chronic Urticaria Quality of Life 
Questionnaire (CU-Q2oL) [20].
In the Urticaria Patient Daily Diary (UPDD), a Sleep 
Interference question prompts patients to report the 
extent to which itch or hives interfered with their sleep 
in the previous 24  h (score range 0–3: 0 =  no interfer-
ence; 1 = mild, little interference with sleep; 2 = moder-
ate interference, awoke occasionally, some interference 
with sleep; 3 = substantial, awake often, severe interfer-
ence with sleep) [18]. A Weekly Sleep Interference Score 
(range 0–21) is the sum of the daily scores; a higher score 
indicates greater sleep interference. The UPDD has been 
validated in adults and adolescents with CIU/CSU [18, 
21].
The MOS-Sleep Scale is a 12-item measure of sleep 
quality within a 4-week recall period [19]. The MOS-
Sleep Scale has been validated in other disease areas, 
including diabetic neuropathic pain [22]. An MOS-Sleep 
scale score of 25.8 has been noted to be the population 
norm [23]. The MOS-Sleep Scale, Sleep Problem Index 
II (SPI-II) includes nine questions assessing sleep distur-
bance, sleep adequacy, somnolence, snoring, and awak-
ening with shortness of breath or headache. SPI-II scores 
range from 0 to 100, with a higher number reflecting 
greater difficulty with sleep.
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The CU-Q2oL is a 23-item questionnaire to measure 
quality of life in patients with chronic urticaria with a 
2-week recall period [20]. The Sleep Problems dimension 
contains five questions about the extent to which urti-
caria has affected limited sleep, difficulty falling asleep, 
waking up during the night, tiredness during the day due 
to lack of sleep, difficulties with concentration, and feel-
ing nervous. Each of item is scored on a five-point scale 
ranging from 1 (not at all) to 5 (extremely); thus the total 
scoring for this dimension ranges from 5 (least difficulty 
with sleep) to 25 (most difficulty with sleep).
Statistical analysis
We compared the changes in MOS-Sleep Scale, UPDD 
Weekly Sleep Interference Score, and CU-Q2oL Sleep 
Problems domain scores from Baseline to each measure-
ment point in the treatment arms with those in the pla-
cebo arms using analysis of covariance t tests, which were 
adjusted for baseline score (less than median, greater 
than or equal to median) and weight (<80, ≥80 kg) and 
individually fit at each time point. All statistical analy-
ses were performed with SAS software (version 9.1; SAS 
Institute Inc., Cary, NC, USA).
We used Pearson correlation coefficient to estimate 
simple correlations among sleep outcomes in all three 
studies (pooled). We also explored the correlations 
between the trajectories of change in the Weekly Urti-
caria Activity Score (UAS7) and two domains of the MOS 
Sleep Scale (daytime somnolence and sleep disturbance) 
in the three studies. For that, we used latent growth mod-
eling [24], wherein individual slopes of change and inter-
cepts for UAS7 and MOS daytime somnolence and sleep 
disturbance were correlated for each patient.
To adjust for the use of diphenhydramine (as a rescue 
medication) and to properly model the correlated nature 
of within-patient observations over time, we conducted 
sensitivity analyses for the UPDD results using repeated-
measures models, which adjusted for baseline score, 
weight, and weekly diphenhydramine dose as a time-var-
ying covariate. A range of covariance structures was con-
sidered in fitting these repeated-measures models, all of 
which yielded very similar results. The final results pre-
sented are extracted from the models that used Toeplitz 
covariance structures, which assume that observations 
equally spaced in time have the same covariance.
Results
Baseline patient characteristics have previously been 
reported [14–16]. At Baseline, patients with CIU/CSU 
reported substantial sleep impairment, with mean MOS-
Sleep Scale, SPI-II scores ranging from 47.4 to 49.2, mean 
UPDD Weekly Sleep Interference Scores ranging from 
11.2 to 12.6, and mean CU-Q2oL Sleep Problems domain 
scores ranging from 45.1 to 49.4 (Table 1).
On average, patients with CIU/CSU in all treatment 
arms experienced improvement in sleep at week 12 
compared with Baseline for all sleep measures (Table 2). 
Patients treated with omalizumab reported a larger 
reduction in sleep problems than those in the placebo 
arm, and omalizumab 300 mg demonstrated best results 
among all study arms as noted in Table 2 [statistically sig-
nificant improvement with omalizumab 300 mg at week 
12 for MOS-Sleep Scale (all three studies), UPDD Weekly 
Sleep Interference Score (ASTERIA I and GLACIAL), 
and CU-Q2oL Sleep Problems domain (GLACIAL)]. 
Patient sleep improved quickly; the largest reduction in 
sleep problems was reported within the first 4 weeks of 
therapy and were maintained over the active treatment 
period. The patterns of sleep improvement are presented 
below according to each medium of assessment.
UPDD Weekly Sleep Interference Scores
As assessed through the UPDD Weekly Sleep Interfer-
ence Score, patients reported improvement in sleep as 
early as week 1, and the most dramatic improvement 
was observed by week 4 (Fig. 1). Further sleep improve-
ment was reported by week 12, and beyond, by week 24 
(in ASTERIA I and GLACIAL). During active treatment 
in all three studies, the omalizumab 300 mg arm demon-
strated the largest improvement compared with all other 
treatment arms as noted in Fig. 1 (statistical significance 
with omalizumab 300 mg at all time points during active 
treatment in all three studies). After the active treatment 
period during which improvements had been observed, 
all omalizumab-treated patients experienced a relapse in 
symptoms, including sleep, although the scores did not 
fully return to baseline values. Placebo-treated patients 
who had not experienced a substantial improvement 
in sleep measures during the active treatment period, 
continued with stable symptoms during the follow-up 
period.
Sensitivity analyses demonstrated similar trends in the 
data; sleep systematically improved over the course of the 
study, and the omalizumab 300  mg arm demonstrated 
the best outcomes (Additional file 1: Figure S1).
MOS‑Sleep Scale, SPI‑II scores
MOS-Sleep Scale, SPI-II scores reflected improvement 
in sleep at the first time of measurement, week 4, after 
which the improvement in sleep was maintained until 
weeks 12 (all studies) and 24 (ASTERIA I and GLACIAL; 
Fig. 2). In all studies, omalizumab 300 mg demonstrated 
the largest improvement compared with the other treat-
ment arms as noted in Fig.  2 (statistically significant 
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Table 1 Baseline sleep impairment
CU‑Q2oL Chronic Urticaria Quality of Life Questionnaire, MOS‑Sleep Scale Medical Outcomes Study Sleep Scale, SPI‑II Sleep Problem Index II, UPDD Urticaria Patient 
Daily Diary
a Number of patients: ASTERIA I: omalizumab 75 mg, n = 76; ASTERIA II: placebo, n = 78; GLACIAL: placebo, n = 82; omalizumab 300 mg, n = 250
b Number of patients: ASTERIA I: placebo, n = 63; omalizumab 75 mg, n = 59; omalizumab 150 mg, n = 63; omalizumab 300 mg, n = 61; ASTERIA II: placebo, n = 69; 
omalizumab 75 mg, n = 70; omalizumab 150 mg, n = 70; omalizumab 300 mg, n = 71; GLACIAL: placebo, n = 79; omalizumab 300 mg, n = 243
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Table 2 Change from Baseline in sleep measures at week 12
CU‑Q2oL Chronic Urticaria Quality of Life Questionnaire, MOS‑Sleep Scale Medical Outcomes Study Sleep Scale, SPI‑II Sleep Problem Index II, UPDD Urticaria Patient 
Daily Diary
Adjusted * p < 0.05; ** p < 0.001; *** p < 0.01, versus placebo
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improvement with omalizumab 300  mg at all measured 
time points during active treatment in all three studies) 
(Fig. 3).
CU‑Q2oL scores
Through the CU-Q2oL questionnaire Sleep Problems 
domain, patients reported the most dramatic improve-
ment in sleep at the first time of assessment (week 4). 
Afterwards, the improvement in sleep was maintained 
or slightly improved through weeks 12 (all studies) and 
24 (ASTERIA I and GLACIAL; Fig. 3). In all three stud-
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Fig. 1 Change in UPDD Weekly Sleep Interference Score. a ASTERIA 
I, b ASTERIA II, and c GLACIAL. Arrows represent omalizumab dosing. 
Low numbers represent good quality sleep. Least‑squares means were 
derived from a repeated‑measures model adjusted for baseline value 
(less than median, greater than or equal to median) and baseline 
weight (<80, ≥80 kg). Statistical significance is marked every 4 weeks 
to minimize the visual burden of the graph. However, the following 
endpoints demonstrated statistical significance, in addition to the 
ones marked on the graph: ASTERIA I: all time points for omalizumab 
300 mg during treatment and follow‑up weeks 25, 34, 37 and 38; 
weeks 9, 10, 11, and 13 for omalizumab 150 mg; and weeks 26, 27, 29, 
30, 31, 33, 34, 37 for omalizumab 75 mg; ASTERIA II: all time points for 
omalizumab 300 mg during treatment and follow‑up weeks 13–15; 
weeks 1, 2, 3, 5, 6, 7, 9, 10, 11, 13, and 21 for omalizumab 150 mg; and 
weeks 1, 2, 10, 13, and 21 for omalizumab 75 mg; GLACIAL: all time 
points during treatment and follow‑up weeks 25, 26, 27, 29, 30, and 
31 for omalizumab 300 mg. *p < 0.05; **p < 0.001; ***p < 0.01, versus 
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Fig. 2 Change in MOS‑Sleep Scale, SPI‑II score: a ASTERIA I, b 
ASTERIA II, and c GLACIAL. Arrows represent omalizumab dosing. Low 
numbers represent good quality sleep. Least‑squares means were 
derived from a repeated‑measures model adjusted for baseline value 
(less than median, greater than or equal to median) and baseline 
weight (<80, ≥80 kg). *p < 0.05; **p < 0.001; ***p < 0.01, versus 
placebo. MOS‑Sleep Scale Medical Outcomes Study Sleep Scale, SPI‑II 
Sleep Problem Index II
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300  mg as noted in Fig.  5 (statistically significant 
improvement with omalizumab 300  mg at all measured 
time points during active treatment in ASTERIA II and 
GLACIAL and at weeks 4 and 8 in ASTERIA I).
Correlation analyses
The correlations between sleep outcomes (Table  3) 
ranged from moderate to strong. The strongest correla-
tion at all time-points was between CU-Q2oL and MOS 
Sleep Scale, Sleep Problem Index-II, possibly reflecting 
longer recall period (2 and 4  weeks, respectively) and 
broader scope of questions than in UPDD Weekly Sleep 
Interference Score, obtained through UPDD, which was 
completed daily. Latent curve modeling revealed correla-
tion between changes in the disease activity and changes 
in sleep. Individual-level changes in UAS7 and MOS 
daytime somnolence were moderately to strongly corre-
lated in ASTERIA I and GLACIAL (Fig.  4). Individual-
level changes in the UAS7 and MOS sleep disturbance 
were moderately correlated in ASTERIA I and GLACIAL 
(Fig.  5). In other words, improvement in itch and hives 
was associated with decreases in somnolence and sleep 
disturbance.
Discussion
Data from the three pivotal studies of omalizumab dem-
onstrated substantial sleep improvement in patients with 
CIU/CSU. Marked improvement in sleep scores was 
observed after the first dose of therapy. As assessed by the 
three scales, the omalizumab 300 mg arms demonstrated 
the greatest improvements among all treatment arms. 
These results suggest that for patients with CIU/CSU and 
disturbed sleep, omalizumab should be considered as a 
potential treatment option, especially if the underlying 
CIU/CSU is uncontrolled despite H1-antihistamines.
Sleep disturbances in dermatologic disorders may sub-
stantially impair health-related quality of life and may be 
associated with serious psychopathology [25]. Sleep dis-
orders in dermatologic conditions may result not only 
because of symptoms such as pruritus causing difficulties 
initiating or maintaining sleep (e.g., insomnia), but also 
through other physiologic mechanisms, including disrup-
tion of the skin’s thermoregulatory function [25, 26]. The 
treatment of sleep disturbance in dermatologic disorders 
such as atopic dermatitis has received considerable atten-
tion, but the impacts of treatment on sleep disturbance 
in CIU/CSU have not been well elucidated [27]. Moreo-
ver, treatments of sleep disturbance in dermatologic dis-
orders often focus on response to sedating medications 
such as hypnotics rather than treatment of the underlying 
condition [27]. Therefore, it is notable that we observed 
improvements in sleep by targeting the underlying der-
matologic disorder.
Grob et  al. [8] reported on sleep impairment in 1356 
adult patients with chronic skin disorders; three groups 
of patients were represented: chronic urticaria, pso-
riasis, and atopic dermatitis. Interference with sleep 
described as “often” or “every night” was reported by 
more than 50 % of patients with chronic urticaria. Sleep-
ing was more problematic in patients with chronic urti-
caria and psoriasis than in those with atopic dermatitis. 
The baseline characteristics of our patient population 
with refractory CIU/CSU symptoms confirm that sleep 
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Fig. 3 Change in CU‑Q2oL Sleep Problems domain. a ASTERIA I, b 
ASTERIA II, and c GLACIAL. Arrows represent omalizumab dosing. Low 
numbers represent good quality sleep. Least‑squares means were 
derived from a repeated‑measures model adjusted for baseline value 
(less than median, greater than or equal to median) and baseline 
weight (<80, ≥80 kg). *p < 0.05; **p < 0.001; ***p < 0.01, versus pla‑
cebo. CU‑Q2oL Chronic Urticaria Quality of Life Questionnaire
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by measurement with the three patient-reported out-
come measurement tools (MOS-Sleep Scale, SPI-II; 
UPDD Weekly Sleep Interference Score; and CU-Q2oL 
Sleep Problems domain).
Although sedating H1-antihistamines work as night-
time therapy for CIU/CSU (to relieve symptoms and 
help with sleep), some patients report their itch and 
hives persist despite such treatment. Over-the-counter 
diphenhydramine lacks consensus recommendation 
in the treatment of chronic insomnia, and some have 
questioned its efficacy and safety [28]. ASTERIA I and 
ASTERIA II demonstrated a dose-dependent reduction 
in the mean number of diphenhydramine tablets/week 
as compared with placebo at Week 12 (ASTERIA I: pla-
cebo, −1.00; 75 mg, −2.29, p =  0.1356; 150 mg, −2.94, 
p = 0.0249; 300 mg, −4.20, p = 0.0001; ASTERIA II: pla-
cebo, −2.21; 75 mg, −2.33, p =  0.9120; 150 mg, −3.72, 
p = 0.0682; 300 mg, −4.14, p = 0.0138); the reduction in 
GLACIAL was not significant (placebo, −2.70, 300  mg, 
−3.92, p =  0.1499). All enrollees in our clinical studies 
were patients with moderate to severe CIU/CSU who 
failed at least 6 weeks of therapy with licensed doses of 
H1-antihistamines. In GLACIAL, H1-antihistamines 
could be used at up to four times the approved dose, 
increasing the possibility of producing a sedating effect. 
This is consistent with previous reports that as much as 
Table 3 Pearson correlation analysis among sleep scores (pooled data)
CU‑Q2oL Chronic Urticaria Quality of Life Questionnaire, MOS‑Sleep Scale Medical Outcomes Study Sleep Scale, SPI‑II Sleep Problem Index II, UPDD Urticaria Patient 
Daily Diary
* p < 0.0001
MOS‑Sleep Scale, SPI‑I UPDD Sleep Interference Score CU‑Q2oL Sleep Problems domain
Sleep outcome
 Baseline
  MOS‑Sleep Scale, SPI‑I
   r 1.00000 0.39454* 0.74655*
   n 970 970 847
  UPDD Weekly Sleep Interference Score
   r 0.39454* 1.00000 0.48848*
   n 970 975 848
  CU‑Q2oL Sleep Problems domain
   r 0.74655* 0.48848* 1.00000
   n 847 848 848
 Week 12
  MOS‑Sleep Scale, SPI‑I
   r 1.00000 0.44790* 0.72307*
   n 828 809 722
  UPDD Weekly Sleep Interference Score
   r 0.44790* 1.00000 0.60849*
   n 809 827 707
  CU‑Q2oL Sleep Problems domain
   r 0.72307* 0.60849* 1.00000
   n 722 707 724
 Week 24
  MOS‑Sleep Scale, SPI‑I
   r 1.00000 0.462952* 0.68932*
   n 494 475 435
  UPDD Weekly Sleep Interference Score
   r 0.46295* 1.00000 0.58334*
   n 475 726 418
  CU‑Q2oL Sleep Problems domain
   r 0.68932* 0.58334* 1.00000
   n 435 418 437
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50 % of patients with CIU/CSU (especially with moderate 
to severe urticaria) fail to respond to up to four times the 
approved dose of H1-antihistamines [6, 29, 30].
Omalizumab use in these patients resulted in improved 
sleep, and this effect was persistent beyond the H1-anti-
histamine background therapy. In GLACIAL, patients 
were allowed to take an H1-antihistamine at up to four 
times the approved dose plus H2-antihistamines, leu-
kotriene receptor antagonists, or both. In ASTERIA I, 
patients were allowed to add 1 additional H1-antihis-
tamine at approved dosing after week 12. Omalizumab 
300  mg demonstrated the best results throughout the 
duration of the study, with the omalizumab 300 mg arms 
exhibiting notable improvement in sleep and retaining it 
through the end of the active treatment period.
Sleep improvement recorded via UPDD Weekly Sleep 
Interference scores appeared to be more pronounced 
than those recorded via CU-Q2oL or MOS-SS. Moreo-
ver, the scores of the latter two instruments correlated 
stronger between themselves than they did with the WSI 
scores. This may appear counter-intuitive in light of the 
fact that MOS-SS is a sleep-specific instrument. The root 
of this phenomenon may lay in the intricacies of the dis-
ease and instruments’ ability to detect change. Because 
CIU/CSU symptoms can wax and wane throughout a 
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Fig. 4 Correlations between change in UAS7 and change in MOS 
daytime somnolence: a ASTERIA I, b GLACIAL. UAS7 Weekly Urticaria 
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Fig. 5 Correlations between change in UAS7 and change in MOS 
sleep disturbance: a ASTERIA I, b GLACIAL. UAS7 Weekly Urticaria 
Activity Score, MOS‑Sleep Scale Medical Outcomes Study Sleep Scale, 
PRO patient‑reported outcomes
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offered by the eDiary (the tool used to collect data from 
WSI scores) rendered more accurate picture of the drug 
effect on the disease than the CU-Q2oL and MOS-SS. 
Because their recall periods comprise 2 and 4  weeks, 
respectively, CU-Q2oL and MOS-SS instruments tend to 
capture the “overall sleep” picture as opposed to the vola-
tility of sleep directly related to CIU/CSU.
Results should be interpreted in light of limitations. 
Minimally important clinical differences for changes 
in sleep measures have not been established in patients 
with CIU/CSU. These analyses are limited by the treat-
ment period of the clinical studies; response to treatment 
for extended periods is not known. Also, the use of over-
the-counter sleep aids was not measured in our study. 
Additionally, although the improvements in patients’ 
underlying CIU/CSU would seem to suggest that this 
is the etiology of improved sleep, we cannot deter-
mine the extent to which this may have been because of 
reduced pruritus versus other potential etiologies, such 
as a more direct physiologic effect of improved derma-
tologic health. However, improvements in symptoms of 
CIU/CSU associated with omalizumab treatment in the 
Phase III trials have been shown to correlate closely with 
improvements in health-related quality of life [31].
Conclusions
Patients with CIU/CSU commonly reported sleep 
impairment at Baseline. Patients treated with omali-
zumab reported improvement in sleep after the first 
dose of omalizumab. Sleep continued to improve with 
subsequent doses, and sleep improvement was evident 
until the end of the active treatment period. The return 
of disease symptoms following discontinuation of active 
treatment was accompanied by a resurgence of sleep 
impairment. Patients receiving omalizumab 300  mg 
achieved greater improvement in sleep than those in 
other treatment arms.
Additional file
Additional file 1: Figure S1. Sensitivity analysis: changes in UPDD 
Sleep Interference score: a ASTERIA I, b ASTERIA II, and c GLACIAL. 
Arrows represent omalizumab dosing. Lower numbers represent better 
sleep. Least‑squares means were derived from a repeated‑measures 
model adjusted for baseline value (<median, ≥median), baseline weight 
(<80 kg, ≥80 kg), and weekly rescue medication (diphenhydramine) dose. 
Statistical significance is marked every 4 weeks to minimize the visual 
burden of the graph. However, the following endpoints demonstrated sta‑
tistical significance, in addition to the ones marked on the graph: ASTERIA 
I: all time points for omalizumab 300 mg; weeks 2, 3, 7, 9, 10, 11, and 13 for 
omalizumab 150 mg; and weeks 1, 2, 5, 6, 10, 11, and 13 for omalizumab 
75 mg; ASTERIA II: all time points for omalizumab 300 mg; weeks 1, 2, 3, 
5, 6, 7, 9, 10, and 11 for omalizumab 150 mg; and weeks 1, 2, 5, 7, 9, 10, 
and 11 for omalizumab 75 mg; GLACIAL: all time points for omalizumab 
300 mg. *p < 0.05; **p < 0.001; ***p < 0.01, versus placebo. UPDD: Urti‑
caria Patient Daily Diary.
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